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Abstract 
 
Enzymatic conversion of arginine to citrulline by peptidyl 
arginine deiminase (PAD) is associated with peptide presentation 
and development of autoimmunity in rheumatoid arthritis. In order to 
facilitate identification of the citrullination site, citrulline residue was 
modified using 4-bromophenyl glyoxal (BPG), and 194 Da mass 
increase and incorporation of the Br signature were confirmed by 
MALDI-TOF MS. Using this approach, we identified four and five 
citrullination sites of bovine serum albumin (BSA) and bovine 
fibrinogen, respectively. MALDI-TOF/TOF MS was used to 
unambiguously identify two citrullination sites from bovine fibrinogen. 
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Citrullination is a post-translational deimination of arginine to 
citrulline catalyzed by peptidyl arginine deiminase (PAD). This enzymatic 
reaction is known to be associated with autoimmune diseases such as 
rheumatoid arthritis (RA) and multiple sclerosis.1,2 Citrullinated proteins 
were increased in sera and synovial fluid of RA patients compared with 
those of osteoarthritis (OA) patients. These citrullinated proteins or peptides 
are suggested to be autoantigens which initiate immune reaction and 
induce systemic inflammation.3,4 Anti-citrullinated protein antibodies have 
been widely used for the diagnosis of RA with 90-98% specificity.5 
Western blot and 2D SDS-PAGE have been used to verify 
citrullination with high sensitivity;6 however, they cannot be used for 
identification of citrullination site. Citrullination occurs only at specific 
arginine residues, and it becomes necessary to identify the citrullination site 
using mass spectrometry. Citrullination is accompanied by only 1 Da 
increase in mass (Fig. 1).7 Therefore, citullinated peptide peaks and the 
isotope peaks from the control peptide overlap on mass spectrum making 
direct observation of citrullination by MALDI-TOF MS difficult. Moreover, 
peptides containing asparagine or glutamine could undergo deamidation 
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with 1 Da mass increase confounding the investigation of citrullination. 
 Several different approaches have been used for investigation of 
citrullination. Isotopic labeling using H2
18O was used for analysis of 
citrullination sites in human fibrinogen by LC-MS.8 LC-MS/MS was used for 
analysis of citrullination sites in nucleophosmin.9 Glyoxal derivatives have 
been known to react with arginine under basic conditions and with citrulline 
under acidic conditions. So, glyoxal derivatives such as phenylglyoxal and 
2,3-butanedione were used for detection of citrulline. Specific modification 
of citrulline has been achieved using a combination of 2,3-butanedione and 
antipyrine or using 2,3-butanedione alone.10-12 Specific binding of citrulline 
to 4-hydroxyphenylglyoxal bonded to beads has been utilized for 
enrichment of citrulline-containing peptides from myelin basic protein for 
subsequent analysis of citrullination sites by MALDI-TOF MS.13 
We attempted to use 4-bromophenylglyoxal (BPG) for 
determination of the citrullination site taking advantage of the unique 
isotopic distribution of Br (79Br, 50.69%; 81Br, 49.31%) as demonstrated in 
earlier mass spectrometric studies.14,15 BPG will react specifically with 
citrulline at low pH and the Br signature with increased mass will facilitate 
mass spectrometric identification of the citrullination site. 
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Trypsin hydrolyzes peptide bond after arginine and lysine, but not 
after citrulline.16 Thus, comparison of the tryptic peptides from citrullinated 
protein with those from control protein can be used to obtain information 
about the citrullination site. A more definitive identification could be derived 
from BPG modification of tryptic peptides from citrullinated protein. 
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2. Experimental section 
 
2.1 Materials 
Bovine fibrinogen, bovine serum albumin (BSA), rabbit skeletal 
muscle peptidyl arginine deiminase 2 (PAD2), trifluoroacetic acid (TFA), α-
cyano-4-hydroxycinnamic acid (CHCA), dithiothreitol (DTT), acetonitrile 
(ACN), glycerol, tris(hydroxymethyl)aminomethane (Tris), Lys-C and trypsin 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). 4-
bromophenylglyoxal hydrate (BPG) was from Ochem Inc (Des Plaines, IL, 
USA). 2-mercaptoethanol was from Bio-Rad (Hercules, CA, USA). Zip-tip 
was from Millipore (Billerica, MA, USA). 
 
2.2 BPG Modification of citrulline 
Model peptides with or without citrulline (IAEFPSRGK-NH2, 
IAEFPScitGK-NH2, VGLGARGHRPYDK-NH2) were synthesized by the 
solid-phase method of Merrifield. 1 mg model peptide was dissolved in 1 ml 
deionized water. 30 μl TFA and 10 μl 50 mM BPG solution were added to 
10 μl of the peptide solution, and the mixture was incubated at 37℃ for 3 h. 
After removing the supernatant using speed-vac, the residue was dissolved 
in 10 μl deionized water and desalted with zip-tip. 
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Proteins (BSA and bovine fibrinogen) were dissolved at 1 mg/ml 
concentration in deimination buffer (80 mM tris-HCl, 8 mM CaCl2, 4 mM 
DTT, 10% glycerol, pH 7.6). PAD (6.5 μl, 2U) was added to 500 μl of the 
protein solution in one tube, and 6.5 μl of the blank solution (20 mM tris-HCl, 
pH 7.4, 10 mM 2-mercaptoethanol, 1 mM EDTA) was added to another 
tube. The PAD reaction was allowed to proceed for 2 h at 37℃. A 10 μl 
aliquot of 0.1 mg/ml trypsin or Lys-C solution in 25 mM ammonium 
bicarbonate was added to both citrullinated and uncitrullinated protein and 
digestion proceeded overnight at 37℃. Peptides in the protein digest were 
treated with BPG as above for model peptides. A portion of the peptides 
from the control proteins was treated with PAD and BPG. 
 
2.3 MALDI-TOF MS 
Matrix solution was made by dissolving 10 mg CHCA in 1 ml of 
50% acetonitrile in water containing 0.1% TFA. 1 μl sample was mixed with 
1 μl of the matrix solution, and 1 μl of the mixture was loaded on a sample 
plate and dried at room temperature. MALDI-TOF and TOF/TOF mass 
spectra were obtained using AutoflexⅡ MALDI time-of-flight mass 
spectrometer (Bruker Daltonics, Bremen, Germany). MALDI-TOF/TOF 
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spectra were also obtained using ABI 4800 Plus MALDI-TOF/TOF analyzer 
(Applied Biosystems, Foster City, CA). 
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3. Results and discussion 
 
3.1 BPG Tagging of Citrulline. 
Citrullination of arginine residue to citrulline catalyzed by PAD and 
subsequent tagging with BPG is schematically shown in Fig. 1. When an 
arginine-containing model peptide (IAEFPSRGK-NH2, 1002.56 Da, Fig. 2a) 
was treated with BPG, no change in the mass spectrum was observed by 
MALDI MS (Fig. 2b). When a similar peptide containing citrulline instead of 
arginine (IAEFPScitGK-NH2, 1003.54 Da, Fig. 2c) was used, a complete 
modification of the peptide with a 194 Da shift accompanied by the Br 
isotopic pattern was observed after reaction with BPG for 3 h (Fig. 2d). 
Without the Br atom, the first isotopic peak is the strongest reflecting low 
abundance of C-13. However, with Br, the third isotopic peak becomes 
stronger than the first. 
The molecular ion generated from BPG-modified IAEFPScitGK-
NH2, observed at m/z 1198.55 (Fig. 2d) was subjected to MS/MS analysis. 
Complete b- and y-series fragment ions were observed in the MS/MS 
spectrum (Fig. 3). The mass difference between y2 and y3 ions was 
consistent with BPG-citrulline. Moreover, the Br signature was observed 
from y3-y8 ions as well as the parent ion, but not from y1 and y2 ions. 
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These results clearly pinpoint the third residue from the C-terminus as the 
citrullination site. The mass difference between b6 and b7 ions was also 
consistent with the BPG-modified citrulline residue. The Br signature was 
observed from b7 and b8 ions, but not from b1-b6 ions.  
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Figure 1. Citrullination by PAD with a mass shift of +1 Da followed by 
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Figure 2. MALDI mass spectra showing an arginine-containing model 
peptide without citrulline before (a) and after (b) reaction with BPG; a model 
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Figure 3. MALDI TOF/TOF spectrum obtained from the m/z 1198.55 peak 
in Fig. 2d 
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3.2 Citrullination sites of BSA 
Since our goal was to identify the PAD-catalyzed citrullination sites 
in proteins utilizing the BPG tag, we next tested the efficacy of the 
citrullination reaction by PAD using BSA. BSA was treated with PAD in the 
presence of Ca2+, which is known to facilitate the citrullination reaction.17 
When the tryptic digest of citrullinated BSA was treated with BPG, mass 
spectrum in Fig. 4b was obtained showing four peptide peaks with the Br 
signature. The original citrullinated peptide without the BPG tag could be 
identified from the mass spectrum in Fig. 4a by subtracting 194 Da from the 
peaks with the Br signature, and the amino acid sequence of the peptide 
could be determined from the BSA database. For example, the BSA 
peptide giving rise to the 1015.52 peak in Fig. 4b was identified as 
FGERALK. Similarly, the 1278.66, 1634.80, and 1663.76 peaks were 
identified as YLYEIARR, RHPEYAVSVLLR, and DTHKSEIAHRFK, 
respectively. 
Both FGERALK and DTHKSEIAHRFK contain one arginine 
residue in between the N- and the C-terminus, which indicates that the R 
residues are citrullinated and thus the peptide bond between R and the 
adjacent residue is not subject to tryptic hydrolysis. Two peptides, 
YLYEIARR and RHPEYAVSVLLR, contain two R residues one of which 
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being at the C-terminus. If the C-terminal R were citrullinated, tryptic 
hydrolysis would have been blocked and such peptides would not have 
been detected. This result implies that citrullination of R is specific and 
depends on the chemical environment around the R residue. When trypsin 
treatment preceded the PAD and BPG reactions, the peptides ending with 
C-terminal R were not observed. For example, FGER which is a tryptic 
fragment of FGERALK was not citrullinated and subsequently detected with 
BPG tag. The same was the case with YLYEIAR and DTHKSEIAHR. Thus 
it appears that several amino acid residues after R are needed for the PAD 
reaction. 
The mass spectrum obtained when BSA was first hydrolyzed with 
Lys-C, which works at the C-terminal side of lysine but not of arginine, and 
treated with PAD and BPG, was identical with the one obtained when BSA 
was first treated with PAD and then hydrolyzed with Lys-C and tagged with 
BPG (result not shown). This implies that citrullination by PAD does not 
depend on the three dimensional structure of a protein, but rather on 
specific residues around the arginine residue. BSA contains 23 arginine 
residues. Peptides observed by MALDI MS (Fig. 4a) covered 55% of the 
entire sequence and represented 18 arginine residues. Of these, only 4 
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residues were identified as citrullinated showing about 20% specificity. 
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Figure 4. MALDI mass spectra obtained from tryptic digest of citrullinated 
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No Observed m/z Sequence Residue 
(1) 1015.52 FGERALK 205-211 
(2) 1278.66 YLYEIARR 137-144 
(3) 1634.80 RHPEYAVSVLLR 336-347 
(4) 1663.76 DTHKSEIAHRFK 1-12 
Table 1. Tryptic BSA peptides detected via citrullination and BPG tagging. 
Citrullinated arginine residues are in bold 
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3.3 Citrullination sites of fibrinogen 
Five peaks showing the BPG tag were observed by MALDI MS 
(Fig. 5) from bovine fibrinogen citrullinated using PAD, treated with Lys-C 
and derivatized with BPG. Lys-C hydrolyzes after lysine, but not after 
arginine. Therefore, analysis of the results is more straightforward using 
Lys-C than trypsin, because trypsin hydrolyzes after the arginine residue 
from the control protein but not after citrullination by PAD. The four peptides 
containing the five citrullinated arginine residues were identified as 
summarized in Table 2. Two peptides were from the alpha chain and 
contained one R residue. A third peptide, VGLGARGHRPYDK, was from 
the beta chain and contained two R residues. 
The three peptides giving rise to the four peaks, labeled 1 through 
4, could be readily identified from the fibrinogen sequence from the 
observed m/z values taking citrullination and BPG tagging into account. 
However, the 1988.64 peak carrying the Br tag did not match any Lys-C 
digested peptide sequence from fibrinogen. MS/MS analysis was 
performed on this ion. A series of fragment ions with the Br signature was 
obtained as shown in Fig. 6. From the mass differences, the 
PTDYDEGQDD could be deduced definitively, which matched residues 3-
12 of the N-terminal peptide from the bovine fibrinogen beta chain. 
- 18 - 
 
Therefore, it appeared that the 1988.64 peak represented the 
QFPTDYDEGQDDRPK sequence (residues 1-15). The ions, y1 and y2, 
corresponding to K and P, respectively, did not carry the Br signature. 
However, y3 and subsequent ions carried the signature clearly identifying 
the R, residue 13, as the citrullination site. The molecular weight of 
QFPTDYDEGQDDRPK is 1809.78 Da and after modification a signal was 
expected at 2004.78 instead of 1988.64. This difference of 16 Da suggests 
some modification of the N-terminal peptide. The nature of the modification 
is unknown.  
It was hoped that the MS/MS spectrum derived from 
VGLGARGHRPYDK with one R citrullinated and derivatized with BPG 
could show which R is citrullinated first. The 1620.70 peak in Fig. 5 was not 
strong enough to yield the desired MS/MS spectrum. Therefore, 
VGLGARGHRPYDK-NH2 was synthesized and citrullinated using PAD. 
After 1 h reaction with PAD followed by BPG tagging, a major peak with the 
Br signature was observed at 1618.99 followed by a smaller peak with 2 
BPG tags. Figure 7 shows the MS/MS spectrum obtained from the 1618.99 
peak. All b-ions up to b-8 did not show the Br signature. The b-9, b-10, and 
the parent ion carried the signature. These results indicate that the R which 
is the 9th residue from the N-terminus is citrullinated first, while the 6th 
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residue R remains uncitrullinated. It appears that the PAD reaction rate is 
influenced by the chemical environment around the R residue. 
It should be noted that as the molecular weight of the peptide 
increases the first isotopic peak decreases making the symmetrical Br 
signature less evident. It was observed from peaks with the Br signature at 
m/z greater than 1400 Da in Fig. 4-6. The distinctly strong third isotopic 
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Figure 5. MALDI mass spectra obtained from peptides of citrullinated 
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Table 2. Peptides from citrullinated bovine fibrinogen giving rise to the 
observed peaks showing the Br signature. Citrullinated arginine residues 










No Observed m/z Sequence Residue 
(1) 1587.64 NIVELMRGDFAK alpha  111-122 
(2) 1620.70 VGLGARGHRPYDK beta   16-28 
(3) 1815.57 VGLGARGHRPYDK beta   16-28 
(4) 1657.62 MSTITGPVPREFK alpha  229-241 
(5) 1988.64 QFPTDYDEGQDDRPK beta   1-15 
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4. Conclusion 
Incorporation of Br signature via 4-bromophenyl glyoxal facilitates 
identification, by MALDI-TOF MS, of the peptide containing arginine residue 
citrullinated by peptidyl arginine deiminase. Unambiguous identification of 
the citrullination site through partial sequencing around the citrullination site 
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알지닌이 시트룰린으로 변형되는 시트룰린화는 peptidyl 
arginine deiminase (PAD)에 의한 효소화 반응으로 류마티스 
관절염과 같은 자가면역질환과 관련되어 있다. 시르툴린화 위치를 
확인하기 위해서, 시트룰린 잔기를 4-bromophenyl glyoxal 
(BPG)를 이용하여 변형하였고, 반응 뒤 194 Da 질량 증가와 
브롬 동위원소 패턴을 MALDI-TOF 질량분석에서 확인하였다. 
이 방법으로 bovine serum albumin (BSA) 에서 4 군데, bovine 
fibrinogen 에서 5 군데의 시트룰린화 위치를 각각 찾아내었다. 
또한, MALDI-TOF/TOF 질량분석을 이용하여 bovine 
fibrinogen의 시트룰린화 위치 두 곳을 명확하게 확인하였다. 
 
주요 단어 : 시트룰린화, 시트룰린, deimination, 4-bromophenyl 
glyoxal, 매트릭스-지원 레이저 탈착 이온화 질량분석기 (MALDI-
TOF MS) 
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